Figure 2.
Uptake of PPRSFL–activatable cell-penetrating peptide (ACPP) correlates with disease progression and neurologic symptoms. (A) Representative experimental autoimmune encephalomyelitis (EAE) clinical score curve illustrates the different time points of PPRSFL-ACPP administration. (B) Quantification of total fluorescent signal in whole spinal cord scans from mice injected with PPRSFL-ACPP at different time points of EAE shows that detection of thrombin activity increases with EAE progression. Data are presented as mean ± standard error of the mean; *p < 0.05, ***p < 0.001, 1-way analysis of variance; n = 5 to 7 per group. (C) Scatter plot shows correlation between total thrombin activity in the entire spinal cord and clinical score of EAE (R2 = 0.86, p < 0.0001, F test). [Color figure can be viewed in the online issue, which is available at www.annalsofneurology.org.]